Cargando…

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure

PURPOSE: To assess the efficacy of one course of rituximab (two 1-g doses) compared to an alternative tumor necrosis factor-α (TNFα) blocker in rheumatoid arthritis patients who had experienced one previous TNFα blocker failure (eg, etanercept, adalimumab, or infliximab). PATIENTS AND METHODS: The e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kekow, Joern, Mueller-Ladner, Ulf, Schulze-Koops, Hendrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402045/ https://www.ncbi.nlm.nih.gov/pubmed/22848150 http://dx.doi.org/10.2147/BTT.S32244

Ejemplares similares

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
por: Listing, Joachim, et al.
Publicado: (2015)

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
por: Huoponen, Saara, et al.
Publicado: (2019)

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial
por: Sigaux, Johanna, et al.
Publicado: (2017)

Rheumatoid Meningoencephalitis: A Feared Condition in the Era of TNF Blockers
por: Figueroa Rodriguez, Fernando, et al.
Publicado: (2018)

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
por: Finckh, A, et al.
Publicado: (2010)

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
por: Finckh, Axel, et al.
Publicado: (2012)

Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
por: Emery, P, et al.
Publicado: (2015)

Restored and Enhanced Memory T Cell Immunity in Rheumatoid Arthritis After TNFα Blocker Treatment
por: Khanniche, Asma, et al.
Publicado: (2019)

Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure
por: Gutierrez-Gonzalez, Luis Arturo, et al.
Publicado: (2013)

CNS Demyelination with TNF-α Blockers
por: Kemanetzoglou, Elissavet, et al.
Publicado: (2017)

Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNFα Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients
por: Arstikyte, Inesa, et al.
Publicado: (2015)

Behҫet’s Disease, and the Role of TNF-α and TNF-α Blockers
por: van der Houwen, Tim, et al.
Publicado: (2020)

Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure
por: Park, Dong-Jin, et al.
Publicado: (2022)

TNF-α and TNF-β Gene Polymorphism in Saudi Rheumatoid Arthritis Patients
por: Al-Rayes, Hannan, et al.
Publicado: (2011)

The Effect of TNF and Non-TNF-Targeted Biologics on Body Composition in Rheumatoid Arthritis
por: Vial, Gaelle, et al.
Publicado: (2021)

New approaches to inhibiting TNF production in rheumatoid arthritis: is pathological TNF regulated in the same way as protective TNF?
por: Feldmann, M, et al.
Publicado: (2001)

T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy
por: Dulic, Sonja, et al.
Publicado: (2017)

Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis
por: Gu, Ki-Nam, et al.
Publicado: (2019)

Efficacy of a second TNF blocker, when the first one failed, in patients with juvenile idiopathic arthritis (JIA)
por: Salmaso, A, et al.
Publicado: (2008)

Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis
por: Nguyen, Dao Xuan, et al.
Publicado: (2016)

Bone and TNF in rheumatoid arthritis: clinical implications
por: Manara, Maria, et al.
Publicado: (2015)

In vitro response pattern of monocytes after tmTNF reverse signaling predicts response to anti-TNF therapy in rheumatoid arthritis
por: Meusch, Undine, et al.
Publicado: (2015)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
por: Gottenberg, Jacques-Eric, et al.
Publicado: (2019)

Hepatorenal pathologies in TNF-transgenic mouse model of rheumatoid arthritis are alleviated by anti-TNF treatment
por: Li, Xuefei, et al.
Publicado: (2023)

Regulatory T cells in rheumatoid arthritis
por: Leipe, Jan, et al.
Publicado: (2005)

The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection
por: Atteno, Mariangela, et al.
Publicado: (2014)

Sustained Remission After Combination Therapy with Rituximab and Etanercept in Two Patients with Rheumatoid Arthritis After TNF Failure: Case Report
por: Feuchtenberger, Martin, et al.
Publicado: (2009)

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
por: Said, Cynthia, et al.
Publicado: (2013)

Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
por: Ramiro, Sofia, et al.
Publicado: (2015)

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER
por: Carmona, Loreto, et al.
Publicado: (2006)

Obstacles to Anti-CD4 Therapy in Rheumatoid Arthritis
por: Kalden, Joachim R, et al.
Publicado: (2000)

Synovial Tissue Response to Treatment with TNF Blockers in Peripheral Spondyloarthritis
por: Paramarta, Jacqueline E, et al.
Publicado: (2011)

Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers
por: Laine, Juha, et al.
Publicado: (2016)

Deficient spontaneous in vitro apoptosis and increased tmTNF reverse signaling-induced apoptosis of monocytes predict suboptimal therapeutic response of rheumatoid arthritis to TNF inhibition
por: Meusch, Undine, et al.
Publicado: (2013)

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2016)

Anti-TNF-α effects on anemia in rheumatoid and psoriatic arthritis
por: Corrado, Addolorata, et al.
Publicado: (2017)

Metabolic Effects of Anti-TNF-α Treatment in Rheumatoid Arthritis
por: Macáková, Kristína, et al.
Publicado: (2023)

Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)

Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF
por: Song, Yun-Jeong, et al.
Publicado: (2020)

The Effect of TNF-α on CHD and the Relationship between TNF-α Antagonist and CHD in Rheumatoid Arthritis: A Systematic Review
por: Qian, Yezhou, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dtcpvtjtai11da14ba95squtib